FDA clears additions to Nellcor's Symphony system
This article was originally published in Clinica
Two additions to Nellcor Puritan Bennett's Symphony patient monitoring system have been cleared by the US FDA. They include a three-lead selectable ECG monitoring option for the Symphony N-3000 pulse oximeter, and the N-3200 display/printer for viewing and printing ECG and other parameters.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.